Navigation Links
Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
Date:12/2/2009

JERUSALEM, Israel, December 2 /PRNewswire/ -- Gamida Cell announced today a feasibility study evaluating the preclinical (animal study) safety and efficacy of a gene therapy product which combines technology from Weill Cornell Medical College and Gamida Cell. The product may have potential to treat inherited anemias such as Cooley's Anemia.

Gamida Cell is developing a series of technologies to expand, ex vivo, populations of stem/progenitor cells. The company's lead product, StemEx(R), comprised of expanded populations of adult stem cells derived from umbilical cord blood (UCB), is used today as an experimental treatment for blood cancers like leukemia and lymphoma (see ExCell trial at http://www.stemexstudy.com).

Using lentivirus-based gene transfer, Weill Cornell is researching methods to successfully transfer intactglobin genes, coding for functional hemoglobin proteins, into hematopoietic (blood) stem cells with the goal of developing a cure for beta-thalassemia, generally known as Cooley's anemia and Sickle cell anemia. These are the most commonly inherited diseases.

"The current treatment for Cooley's and sickle cell anemia is chronic blood transfusion, which is used to prevent an otherwise likely fatal outcome. Stem cell-based gene transfer, an ex vivo procedure commonly known as transduction, offers a potential means to cure these diseases through the permanent integration of potentially therapeutic genes into the hematopoietic stem cells of the patient. The limitation of this therapy is the low number of transduced stem cells. Expanding the number of transduced stem cells in vitro before reinfusion offers the possibility of creating a more effective therapy and consequently, a potential cure. Using Gamida Cell's expansion technology, we hope to transfer a substantively increased number of stem cells, transduced with an intact globin gene coding for a functional hemoglobin protein, through an expanded population of hematopoietic stem cells, large enough to make a therapeutic impact," said Dr. Stefano Rivella, assistant professor of genetic medicine in pediatrics at Weill Cornell Medical College.

"This initiative is of great importance as it could lead to some revolutionary breakthrough science. It also demonstrates yet another example of how Gamida Cell's proprietary technology can complement other existing technologies to potentially find cures for deadly and chronic diseases," said Tony Peled, chief scientific officer and vice president of research & development of Gamida Cell.

In the event the effort is successful, Gamida Cell and Weill Cornell will have the option to enter into further co-development and commercialization agreements.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological, autoimmune and ischemic diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's flagship product, StemEx, is now being studied as a therapy for patients with blood cancers in an international pivotal trial at leading transplant centers in the U.S., Europe and Israel. StemEx has orphan drug designation in the U.S. and in Europe. Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceutical Industries, Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com. For information regarding the ExCell study: http://www.stemexstudy.com.

    Press contact:
    Marjie Hadad
    Media Liaison/IR
    Gamida Cell
    +972-54-536-5220
    marjie@gamida-cell.com

SOURCE Gamida Cell LTD


'/>"/>
SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Gamida Cell and Cellerix Partner on Feasibility Study
2. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
3. Simcere Announces 105 Drugs Included in Chinas National Drug Reimbursement List
4. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
5. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
6. Ohio Capital Fund Announces Sponsorship of Minority Business Conference
7. Cadient Interactive Announces the Launch of HATCH Consulting Services
8. Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics
9. The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinsons Disease Treatments
10. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
11. Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... Florida (PRWEB) , ... October 11, 2017 , ... ... Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 ... for the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
Breaking Biology Technology:
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
Breaking Biology News(10 mins):